The oncolytic virotherapy treatment platform for cancer: Unique biological and biosafety points to consider

Richard Vile, Dale Ando, David Kirn

Research output: Contribution to journalReview article

71 Scopus citations

Abstract

The field of replication-selective oncolytic viruses (virotherapy) has exploded over the last 10 years. As with many novel therapeutic approaches, initial overexuberance has been tempered by clinical trial results with first-generation agents. Although a number of significant hurdles to this approach have now been identified, novel solutions have been proposed and improvements are being made at a furious rate. This article seeks to initiate a discussion of these hurdles, approaches to overcome them, and unique safety and regulatory issues to consider.

Original languageEnglish (US)
Pages (from-to)1062-1067
Number of pages6
JournalCancer Gene Therapy
Volume9
Issue number12
DOIs
StatePublished - Dec 1 2002

Keywords

  • Cancer
  • Experimental therapeutics
  • Oncolytic
  • Virotherapy

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Cancer Research

Fingerprint Dive into the research topics of 'The oncolytic virotherapy treatment platform for cancer: Unique biological and biosafety points to consider'. Together they form a unique fingerprint.

  • Cite this